Fifth Third Bancorp

🇺🇸NASDAQ Global Select
Back to all articles
Fifth Third Bancorp stock analysis FITB overview
Slightly Bullish +25

OptimizeRx Secures New Credit Facility to Boost Flexibility

📅 OptimizeRx entered a new $35 million senior secured credit facility with Fifth Third Bank on May 7, 2026.

💰 The financing includes a $25 million term loan and a $10 million revolving line to refinance an existing October 2023 debt.

🔄 The facility is structured as a seven-year agreement with an accordion feature allowing for up to $25 million in additional borrowing.

📉 Q4 2026 revenue declined by 10% year-over-year to $19.8 million due to most-favored-nation pricing pressures and cautious client spending.

📉 GAAP net loss narrowed to $0.5 million in the same period, while adjusted EBITDA more than doubled to $3.3 million.

💸 The company paid down $2.7 million of principal debt and updated its 2026 revenue guidance to between $95 million and $100 million.

🛠️ Management launched efficiency initiatives expected to generate $3 million in annualized savings, with $1 million realized this year.

🏥 Revenue concentration with the top 20 pharmaceutical companies has moderated to 52%, indicating diversification across mid-tier clients.

📈 Net revenue retention stood at 110% over the twelve months ended March 31, demonstrating strong sales performance.

💡 OptimizeRx aims to lower annual interest expenses by approximately $1.5 million with the new leverage-based pricing structure.

🤖 The company continues to integrate programmatic DSP access into its EHR network for hyper-local digital engagement strategies.

🎯 Analysts maintain a Buy rating on OPRX stock with a price target of $20.00, citing improved financial health and low leverage.

Full Analysis
OptimizeRx (OPRX) announced on May 7, 2026, that it has secured a new $35 million senior secured credit facility with Fifth Third Bank to replace its existing term loan. The new agreement consists of a $25 million term loan and a $10 million revolving credit line with an accordion feature allowing for up to an additional $25 million in future borrowings. Management states the refinancing is designed to lower annual interest expense by approximately $1.5 million, provide balance sheet flexibility, fund potential stock repurchases, and support working capital needs. The facility carries seven-year terms, leverage-based pricing, and customary covenants with guarantees. Financially, OptimizeRx reported first quarter results ended March 31, 2026, showing a 10% year-over-year decline in revenue to $19.8 million due to near-term headwinds such as most-favored-nation pricing pressures and cautious client spending. Despite the revenue miss, the company narrowed its GAAP net loss to $0.5 million and more than doubled adjusted EBITDA to $3.3 million, supported by higher non-GAAP profitability and a debt paydown of $2.7 million in principal. Management updated its full-year 2026 revenue guidance to a range of $95 million to $100 million while maintaining unchanged adjusted EBITDA targets of $21 million to $25 million. Operationally, the company cites solid traction with clients less exposed to MFN pricing, particularly among mid-tier and emerging life sciences companies, noting that revenue concentration with the top 20 pharmaceutical companies has moderated to 52%. Net revenue retention stood at 110% over the twelve months ended March 31. The firm is launching efficiency initiatives expected to yield $3 million in annualized savings, including $1 million this year, and is integrating programmatic demand-side platform access into its electronic health record network to strengthen its competitive position. Analyst sentiment remains mixed with a Buy rating from a recent analyst featuring a $20.00 price target, while TipRanks’ AI gives the stock a Neutral score citing improved financial health but weak technical trends and a high P/E ratio.